
Test for overall effect: Z = 0.54 (P = 0.59)

Appendix 16c: Forest plots for clinical evidence reviews on psychological vs. pharmacological interventions, combination therapy and other medical interventions

Psychological vs. Pharmacological (OCD); Combination therapy (OCD); Other medical interventions




0.01

0.1

Favours CBT

10


Favours Clomipramine



Favours CBT Favours Clomipramine

Review: OCD: psychological v pharmacological


03 Children: CBT v Sertraline Comparison: 01 Leaving the study early Outcome:



Review: OCD: psychological v pharmacological 03 Children: CBT v Sertraline


Comparison:

02 CY-BOCS



Combination therapy (OCD)

Review: OCD: combination therapy
Comparison: 01 ERP+ SRI v ERP
Outcome: 01 Leaving the study early



Review: OCD: combination therapy

Comparison: 01 ERP+ SRI v ERP

Outcome: 02 Leaving the study early due to adverse effects

Study or sub-category	ERP+ SRI ERP RR (fixed) n/N n/N 95% CI			RR (fixed) 95% Cl
01 ERP + Fluvoxamine v ERP	+ placebo			
Cottraux 1990	2/20	1/20		2.00 [0.20, 20.33]
Subtotal (95% CI)	2/20	1/20		2.00 [0.20, 20.33]
Test for heterogeneity: not a	pplicable		 -	
Test for overall effect: Z = 0	.59 (P = 0.56)			
		0.0	1 0.1 1 10	100

Favours ERP+SRI Favours ERP


Review: OCD: combination therapy

Comparison: 01 ERP+ SRI v ERP

Outcome: 03 Non-responders (Y-BOCS 35%)

Study or sub-category	BT + SRI n/N	BT n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 MBT + Fluvoxamine v MBT	Γ + placebo			
Hohagen 1998	3/24	10/25		0.31 [0.10, 1.00]
Subtotal (95% CI)	3/24	10/25	-	0.31 [0.10, 1.00]
Test for heterogeneity: not ap	pplicable		_	
Test for overall effect: $Z = 1$.	96 (P = 0.05)			
		(0.01 0.1 1 10	100
			Favours BT+SRI Favours BT	

OCD: combination therapy Review: 01 ERP+ SRI v ERP Comparison: 04 Non-responders (CGI) Outcome:



Favours ERP+SRI Favours ERP

Favours ERP+SRI Favours ERP

Favours ERP+SRI Favours ERP

OCD: combination therapy Review:

Comparison: 01 ERP+ SRI v ERP


Outcome: 06 Global criterion of non-improvement (duration of rituals)

Study	ERP + SRI	ERP	RR (fixed)	RR (fixed)		
or sub-category	n/N n/N 95% CI		95% CI	95% CI		
01 ERP + Fluvoxamine v ERP	+ placebo: post-treatment					
Cottraux 1990	9/20	14/20		0.64 [0.37, 1.13]		
Subtotal (95% CI)	9/20	14/20		0.64 [0.37, 1.13]		
Test for heterogeneity: not ap	plicable		-			
Test for overall effect: $Z = 1$.	54 (P = 0.12)					
02 ERP + Fluvoxamine v ERP	+ placebo: 6 months follow-up) 				
Cottraux 1990	11/20	14/20		0.79 [0.48, 1.28]		
Subtotal (95% CI)	11/20	14/20	-	0.79 [0.48, 1.28]		
Test for heterogeneity: not ap	plicable		-			
Test for overall effect: $Z = 0$.	97 (P = 0.33)					
03 ERP + Fluvoxamine v ERP	+ placebo: 1 year follow-up					
Cottraux 1990	11/20	12/20		0.92 [0.54, 1.56]		
Subtotal (95% Cl)	11/20	12/20		0.92 [0.54, 1.56]		
Test for heterogeneity: not ap	pplicable		T	,		
Test for overall effect: $Z = 0$.	•					

Review: OCD: combination therapy 01 ERP+ SRI v ERP Comparison:

Study or sub-category	N	ERP + SRI Mean (SD)	N	ERP Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 ERP + Fluvoxamine v ERI	P					
van Balkom 1998	18	12.60(6.60)	19	17.10(8.40)		-0.58 [-1.24, 0.08]
ubtotal (95% CI)	18		19		•	-0.58 [-1.24, 0.08]
est for heterogeneity; not :	applicable				-	
est for overall effect: Z = 1	1.73 (P = 0.08)					
02 MBT + Fluvoxamine v ME	BT + placebo					
Hohagen 1998	24	12.40(6.80)	25	15.90(7.90)		-0.47 [-1.03, 0.10]
Subtotal (95% CI)	24		25		•	-0.47 [-1.03, 0.10]
Test for heterogeneity: not a	applicable					
Test for overall effect: Z = 1	1.61 (P = 0.11)					
03 ERP + Clomipramine v ER	rP					
Foa 2005	19	10.50(8.20)	21	11.00(7.90)	-+ -	-0.06 [-0.68, 0.56]
Subtotal (95% CI)	19		21		•	-0.06 [-0.68, 0.56]
Fest for heterogeneity: not a	applicable				Ī	
Test for overall effect: Z = 0	0.19 (P = 0.85)					
Total (95% CI)	61		65		•	-0.37 [-0.72, -0.01]
Test for heterogeneity: Chi²	= 1.46, df $= 2$ (F	P = 0.48), I ² = 0%				
Test for overall effect: $Z = 2$	2.04 (P = 0.04)					

Review: OCD: combination therapy Comparison: 01 ERP+ SRI v ERP 08 Padua Inventory Outcome SMD (fixed) SMD (fixed) Study ERP or sub-category N Mean (SD) N Mean (SD) 95% CI 95% CI 01 ERP + Fluvoxamine v ERP van Balkom 1998 18 43.20(23.50) 19 57.20(20.60) -0.62 [-1.28, 0.04] Subtotal (95% CI) 18 19 -0.62 [-1.28, 0.04] Test for heterogeneity: not applicable Test for overall effect: Z = 1.84 (P = 0.07) ò Favours ERP+SRI Favours ERP OCD: combination therapy Review: Comparison: 01 ERP+ SRI v ERP Outcome 09 Depression scales (post treatment) Study BT+ SRI SMD (fixed) SMD (fixed) BT Mean (SD) Mean (SD) 95% CI 95% CI or sub-category 01 ERP + Fluvoxamine v ERP van Balkom 1998 -1.19 [-1.89, -0.48] -1.19 [-1.89, -0.48] 18 10.10(7.20) 19 19.90(8.80) Subtotal (95% CI) 18 19 Test for heterogeneity: not applicable Test for overall effect: Z = 3.30 (P = 0.0010) 02 MBT + Fluvoxamine v MBT + placebo Hohagen 1998 -0.25 [-0.82, 0.31] 11.50(9.20) 25 14.00(10.20) Subtotal (95% CI) 25 -0.25 [-0.82, 0.31] Test for heterogeneity: not applicable Test for overall effect: Z = 0.88 (P = 0.38) 03 ERP + Fluvoxamine v ERP + placebo Cottraux 1990 16 9.12(6.03) 15 15.13(5.74) -0.99 [-1.75, -0.24] Subtotal (95% CI) 16 15 -0.99 [-1.75] -0.241 Test for heterogeneity: not applicable Test for overall effect: Z = 2.59 (P = 0.010) 04 Exposure + Clomipramine v Exposure + placebo (at 7 weeks) Marks 1980 16.50(11.10) -0.82 [-1.74, 0.10] 8.10(8.30) 10 10 Subtotal (95% CI) -0.82 [-1.74, 0.10] Test for heterogeneity: not applicable Test for overall effect: Z = 1.75 (P = 0.08) -0.73 [-1.08, -0.38] 69 Test for heterogeneity: Chi² = 4.90, df = 3 (P = 0.18), l² = 38.8% Test for overall effect: Z = 4.07 (P < 0.0001) Favours BT+SRI Favours BT OCD: combination therapy Review: Comparison 01 ERP+ SRI v ERP Outcome: 10 Hamilton Depression Rating scale (follow-up) ERP+ SRI **ERP** SMD (fixed) SMD (fixed) Study Ν Mean (SD) or sub-category Mean (SD) 01 ERP + Fluvoxamine v ERP + placebo (6 months follow-up) Cottraux 1990 -0.17 [-0.94, 0.60] 10.71(6.27) 12.17(10.38) 14 12 -0.17 [-0.94, 0.60] Test for heterogeneity: not applicable Test for overall effect: Z = 0.43 (P = 0.67) 02 ERP + Fluvoxamine v ERP + placebo (1 year follow-up) Cottraux 1990 11.80(7.90) 11 9.50(7.90) 0.28 [-0.54, 1.10] Subtotal (95% CD) 12 1.1 0.28 [-0.54, 1.10] Test for heterogeneity: not applicable Test for overall effect: Z = 0.67 (P = 0.50) -2 Ò Favours ERP+SRI Favours ERP Review: OCD: combination therapy Comparison: 01 ERP+ SRI v ERP Outcome 11 Symptom Checklist-90 Study BT + SRI ВТ SMD (fixed) SMD (fixed) or sub-category N Mean (SD) N Mean (SD) 95% CI 95% CI 01 ERP + Fluvoxamine v ERP van Balkom 1998 -0.54 [-1.20, 0.11] 18 154.50(51.40) 19 184.30(55.50) Subtotal (95% CI) -0.54 [-1.20, 0.11] 18 Test for heterogeneity: not applicable Test for overall effect: Z = 1.62 (P = 0.10) Favours BT+SRI Favours BT



Review: OCD: combination therapy Comparison: 01 ERP+ SRI v ERP Outcome: 18 CGI - patient rating SMD (fixed) SMD (fixed) Study or sub-category N Mean (SD) N Mean (SD) 95% CI 95% CI 01 MBT + Fluvoxamine v MBT + placebo Hohagen 1998 24 -8.00(1.30) 25 -7.00(2.60) -0.48 [-1.04, 0.09] Subtotal (95% CI) 24 25 -0.48 [-1.04, 0.09] Test for heterogeneity: not applicable Test for overall effect: Z = 1.64 (P = 0.10) ò Favours BT+SRI Favours BT OCD: combination therapy Review: Comparison: 01 ERP+ SRI v ERP Outcome 19 Compulsive activity checklist (post treatment) SMD (fixed) SMD (fixed) Study BT + SRI BT Mean (SD) Mean (SD) 95% CI 95% CI or sub-category 01 ERP + Fluvoxamine v ERP + placebo (post treatment) Cottraux 1990 -0.53 [-1.25, 0.19] -0.53 [-1.25, 0.19] 16 14.56(17.38) 15 24.33(18.36) Subtotal (95% CI) 15 16 Test for heterogeneity: not applicable Test for overall effect: Z = 1.45 (P = 0.15) 02 Exposure + Clomipramine v Exposure + placebo; assessor-rated (at 7 weeks) -0.59 [-1.49, 0.31] Marks 1980 10 20.10(15.60) 10 31.30(20.50) Subtotal (95% CI) 10 10 -0.59 [-1.49, 0.31] Test for heterogeneity: not applicable Test for overall effect: Z = 1.28 (P = 0.20) Total (95% CI) 25 -0.55 [-1.12, 0.01] Test for heterogeneity: $Chi^2 = 0.01$, df = 1 (P = 0.92), $I^2 = 0\%$ Test for overall effect: Z = 1.94 (P = 0.05) Ó Favours BT+SRI Favours BT Review: OCD: combination therapy Comparison: 01 ERP+ SRI v ERP Outcome 20 Compulsive activity checklist (follow-up) Study ΒТ SMD (fixed) SMD (fixed) or sub-category Mean (SD) N Mean (SD) 95% CI 95% CI 01 ERP + Fluvoxamine v ERP + placebo (1 year follow-up) Cottraux 1990 -0.47 [-1.30, 0.36] 15.50(17.60) 24.80(20.80) 12 11 -0.47 [-1.30, 0.36] Subtotal (95% CI) Test for heterogeneity: not applicable Test for overall effect: Z = 1.10 (P = 0.27)Favours BT+SRI Favours BT Review: OCD: combination therapy 01 ERP+ SRI v ERP Comparison: 21 Target rituals (assessor): time (post-treatment) SMD (fixed) ВТ SMD (fixed) Study BT + SRI Mean (SD) Ν Mean (SD) 95% CI 95% CI or sub-category 01 ERP + Fluvoxamine v ERP + placebo (post treatment) Cottraux 1990 16 8.50(7.30) 15 15.60(9.20) -0.84 [-1.57, -0.10] Subtotal (95% CI) -0.84 [-1.57, -0.10] 16 15 Test for heterogeneity: not applicable Test for overall effect: Z = 2.22 (P = 0.03) 02 Exposure + Clomipramine v Exposure + placebo (at 7 weeks) Marks 1980 10 2.10(2.10) 10 3.90(2.40) -0.76 [-1.68, 0.15] Subtotal (95% CI) 10 -0.76 [-1.68, 0.15] Test for heterogeneity: not applicable Test for overall effect: Z = 1.64 (P = 0.10) 25 -0.81 [-1.38, -0.23] Test for heterogeneity: $Chi^2 = 0.01$, df = 1 (P = 0.91), $I^2 = 0\%$ Test for overall effect: Z = 2.75 (P = 0.006) Ó Favours BT+SRI Favours BT

Test for overall effect: Z = 0.11 (P = 0.91)

OCD: combination therapy Review: Comparison: 01 ERP+ SRI v ERP Outcome: 22 Target rituals (assessor): time (follow-up) SMD (fixed) SMD (fixed) Study or sub-category Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 ERP + Fluvoxamine v ERP + placebo (6 months follow-up) Cottraux 1990 10.30(8.70) 12 11.90(9.70) -0.17 [-0.94, 0.60] 14 Subtotal (95% CI) 14 12 -0.17 [-0.94, 0.60] Test for heterogeneity: not applicable Test for overall effect: Z = 0.43 (P = 0.67) 02 ERP + Fluvoxamine v ERP + placebo (1 year follow-up) Cottraux 1990 12 9.70(9.90) 11 9.40(6.90) 0.03 [-0.78, 0.85] Subtotal (95% CI) 12 11 0.03 [-0.78, 0.85] Test for heterogeneity: not applicable Test for overall effect: Z = 0.08 (P = 0.94) 0 2 Favours BT+SRI Favours BT Review: OCD: combination therapy Comparison: 01 ERP+ SRI v ERP 23 Target rituals (assessor): discomfort (post-treatment) Outcome: SMD (fixed) BT + SRI ВΤ SMD (fixed) or sub-category Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 ERP + Fluvoxamine v ERP + placebo (post treatment) Cottraux 1990 10.25(8.04) 17.00(8.35) -0.80 [-1.54, -0.07] Subtotal (95% CI) 15 -0.80 [-1.54, -0.07] Test for heterogeneity: not applicable Test for overall effect: Z = 2.14 (P = 0.03) 02 Exposure + Clomipramine v Exposure + placebo (at 7 weeks) Marks 1980 10 2.90(2.00) 10 4.90(1.80) -1.01 [-1.95, -0.06] Subtotal (95% CI) 10 10 -1.01 [-1.95, -0.06] Test for heterogeneity: not applicable Test for overall effect: Z = 2.09 (P = 0.04) Total (95% CI) 25 -0.88 [-1.46, -0.30] Test for heterogeneity: Chi² = 0.11, df = 1 (P = 0.74), l² = 0% Test for overall effect: Z = 2.97 (P = 0.003) Π Favours BT+SRI Favours BT Review: OCD: combination therapy 01 ERP+ SRLV ERP Comparison: Outcome: 24 Target rituals (assessor): discomfort (follow-up) Study BT + SRI BΤ SMD (fixed) SMD (fixed) Ν Mean (SD) or sub-category Mean (SD) 95% CI 95% CI 01 ERP + Fluvoxamine v ERP + placebo (6 months follow-up) Cottraux 1990 14 12.21(9.25) 12 13.30(9.80) -0.11 [-0.88, 0.66] Subtotal (95% CI) -0.11 [-0.88, 0.66] 14 12 Test for heterogeneity; not applicable Test for overall effect: Z = 0.28 (P = 0.78) 02 ERP + Fluvoxamine v ERP + placebo (1 year follow-up) 0.05 [-0.77, 0.87] Cottraux 1990 11.00(9.10) 11.50(10.90) 11 12 0.05 [-0.77, 0.87] Test for heterogeneity: not applicable

Favours BT+SRI Favours BT

Review: OCD: combination therapy Comparison: 01 ERP+ SRI v ERP Outcome: 25 Target rituals (assessor): duration per day SMD (fixed) SMD (fixed) Study or sub-category Mean (SD) N Mean (SD) 95% CI 95% CI 01 ERP + Fluvoxamine v ERP + placebo (post treatment) Cottraux 1990 3.93(2.26) 15 5.40(2.19) -0.64 [-1.37, 0.08] 16 Subtotal (95% CI) 15 -0.64 [-1.37, 0.08] Test for heterogeneity: not applicable Test for overall effect: Z = 1.74 (P = 0.08) 02 ERP + Fluvoxamine v ERP + placebo (6 months follow-up) Cottraux 1990 14 4.00(2.80) 12 4.67(2.27) -0.25 [-1.03, 0.52] Subtotal (95% CI) 14 12 -0.25 [-1.03, 0.52] Test for heterogeneity: not applicable Test for overall effect: Z = 0.64 (P = 0.52) 03 ERP + Fluvoxamine v ERP + placebo (1 year follow-up) Cottraux 1990 2.70(2.70) 11 3.30(2.70) -0.21 [-1.04, 0.61] 12 Subtotal (95% CI) -0.21 [-1.04, 0.61] Test for heterogeneity: not applicable Test for overall effect: Z = 0.51 (P = 0.61) Favours BT+SRI Favours BT OCD: combination therapy Review: 01 ERP+ SRI v ERP Comparison: 26 Behavioural avoidance test: discomfort (post treatment) SMD (fixed) ΒT SMD (fixed) Study BT + SRI Mean (SD) Mean (SD) or sub-category 95% CI 95% CI 01 ERP + Fluvoxamine v ERP + placebo (post treatment) Cottraux 1990 16 9.12(6.55) 15 15.61(7.61) -0.89 [-1.64, -0.15] Subtotal (95% CI) -0.89 [-1.64, -0.15] 16 15 Test for heterogeneity: not applicable Test for overall effect: Z = 2.35 (P = 0.02) 02 Exposure + Clomipramine v Exposure + placebo (at 7 weeks) 10 15.40(11.90) 10 16.90(10.00) -0.13 [-1.01, 0.75] Subtotal (95% CI) 10 -0.13 [-1.01, 0.75] Test for heterogeneity: not applicable Test for overall effect: Z = 0.29 (P = 0.77)Total (95% CI) 25 -0.57 [-1.14, -0.01] Test for heterogeneity: $Chi^2 = 1.69$, df = 1 (P = 0.19), $I^2 = 40.7\%$ Test for overall effect: Z = 1.98 (P = 0.05) Favours BT+SRI Favours BT OCD: combination therapy Review: Comparison: 01 ERP+ SRI v ERP Outcome: 27 Behavioural avoidance test: discomfort (follow-up) BT + SRI ΒТ SMD (fixed) SMD (fixed) Study N Mean (SD) or sub-category Mean (SD) 01 ERP + Fluvoxamine v ERP + placebo (1 year follow-up) Cottraux 1990 -0.14 [-0.96, 0.68] 10.20(9.20) 11.50(9.20) 12 11 -0.14 [-0.96, 0.68] Test for heterogeneity: not applicable Test for overall effect: Z = 0.33 (P = 0.74) Favours BT+SRI Favours BT Review: OCD: combination therapy Comparison: 02 ERP + Clomipramine v Clomipramine Outcome: 01 Leaving the study early RR (fixed) RR (fixed) Study BT + Clomipramine Clomipramine or sub-category n/Ν n/Ν 95% CL 95% CL Foa 2005 14/33 20/47 1.00 [0.59, 1.67] Total (95% CI) 33 47 1.00 [0.59, 1.67] Total events: 14 (BT + Clomipramine), 20 (Clomipramine) Test for heterogeneity: not applicable Test for overall effect: Z = 0.01 (P = 0.99) 0.2 0.5 10 5

Favours BT+CMI Favours CMI

Review: OCD: combination therapy 02 ERP + Clomipramine v Clomipramine Comparison: Outcome: 03 Non-responders (CGI) Study or sub-category nΝ Foa 2005 12/33 Total (95% CI) 33 Test for heterogeneity: not applicable Test for overall effect: Z = 2.50 (P = 0.01) OCD: combination therapy Review 02 ERP + Clomipramine v Clomipramine Comparison: 05 Y-BOCS Outcome: Study

BT + Clomipramine Clomipramine RR (fixed) RR (fixed) 95% CI 95% CI n/N 0.53 [0.33, 0.87] 32/47 47 0.53 [0.33, 0.87] Total events: 12 (BT + Clomipramine), 32 (Clomipramine)

> 0.1 0.2

> > Favours BT+CMI Favours CMI

5 10

Favours BT+CMI Favours CMI

Favours Anti-ERP+FLV

0.5

BT + Clomipramine Clomipramine SMD (fixed) SMD (fixed) Ν or sub-category Ν Mean (SD) Mean (SD) 95% CI 95% CI Foa 2005 10.50(8.20) 27 18.20(7.80) -0.95 [-1.57, -0.33] Total (95% CI) 19 27 -0.95 [-1.57, -0.33] Test for heterogeneity; not applicable Test for overall effect: Z = 3.00 (P = 0.003) ń

Review: OCD: combination therapy

Comparison: 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine

Outcome: 01 Leaving the study early

Study ERP+Fluvoxamine Anti-ERP+Fluvoxamine RR (fixed) RR (fixed) 95% CI 95% CI or sub-category n/Ν n/N Cottraux 1990 4/20 7/20 0.57 [0.20, 1.65] Total (95% CI) 4/20 7/20 0.57 [0.20, 1.65] Test for heterogeneity: not applicable Test for overall effect: Z = 1.03 (P = 0.30) 0.2 0.5

Favours ERP+FLV

Review: OCD: combination therapy

Comparison: 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine 02 Leaving the study early due to adverse effects Outcome:

Anti-ERP+Fluvoxamine RR (fixed) RR (fixed) Study ERP+Fluvoxamine or sub-category n/Ν n/Ν 95% CL 95% CL Cottraux 1990 2/20 2/20 1.00 [0.16, 6.42] Total (95% CI) 2/20 2/20 1.00 [0.16, 6.42] Test for heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.00) 0.1 0.2 0.5 2 5 10 Favours ERP+FLV Favours Anti-ERP+FLV

Review: OCD: combination therapy

03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine Comparison:

Outcome: 03 Global criterion of non-improvement (duration of rituals)

Study or sub-category	ERP+Fluvoxamine n/N	Anti-ERP+Fluvoxamine n/N	RR (fixed) 95% Cl	RR (fixed) 95% CI
01 Post-treatment				
Cottraux 1990	9/20	13/20		0.69 [0.39, 1.24]
Subtotal (95% CI)	9/20	13/20		0.69 [0.39, 1.24]
Test for heterogeneity; not applical	ole		-	·
Test for overall effect: Z = 1.24 (P	= 0.22)			
02.6 months follow-up				
Cottraux 1990	11/20	15/20		0.73 [0.46, 1.17]
Subtotal (95% CI)	11/20	15/20	<u>-</u>	0.73 [0.46, 1.17]
Test for heterogeneity; not applical	ole		_	
Test for overall effect: Z = 1.29 (P	= 0.20)			
03.1 year follow-up				
Cottraux 1990	11/20	14/20		0.79 [0.48, 1.28]
Subtotal (95% CI)	11/20	14/20		0.79 [0.48, 1.28]
Test for heterogeneity; not applical	ole		-	,
Test for overall effect: Z = 0.97 (P				
		0.1	0.2 0.5 1 2 5	10

Favours ERP+FLV Favours Anti-ERP+FLV

Review:

OCD: combination therapy 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine Comparison:

Outcome: 04 Hamilton Depression Scale

Study or sub-category	N E	RP+Fluvoxamine Mean (SD)	Anti N	-ERP+Fluvoxamine Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Post treatment						
Cottraux 1990	16	9.12(6.03)	13	10.46(6.98)	<u> </u>	-0.20 [-0.94, 0.53]
Subtotal (95% CI)	16		13		→	-0.20 [-0.94, 0.53]
Test for heterogeneity: not applica	ble]	
Test for overall effect: $Z = 0.54$ (P	= 0.59)					
02 6 months follow-up						
Cottraux 1990	14	10.71(6.27)	11	11.27(6.02)	<u> </u>	-0.09 [-0.88, 0.70]
Subtotal (95% CI)	14		11		•	-0.09 [-0.88, 0.70]
Test for heterogeneity: not applica	ble				Ī	
Test for overall effect: $Z = 0.22$ (P	= 0.83)					
03.1 year follow-up						
Cottraux 1990	12	11.80(7.90)	10	8.50(3.80)	—	0.50 [-0.36, 1.35]
Subtotal (95% CI)	12		10			0.50 [-0.36, 1.35]
Test for heterogeneity: not applica	ble				*	
Test for overall effect: $Z = 1.14$ (P	= 0.25)					
					-10 -5 0 5	10

Favours ERP + FLV Favours Anti-ERP+FLV

Review:

OCD: combination therapy 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine 05 Target rituals (assessor): time Comparison:

Outcome:

Study or sub-category	N E	RP+Fluvoxamine Mean (SD)	Anti N	i-ERP+Fluvoxamine Mean (SD)			D (fixed) 15% Cl			SMD (fixed) 95% Cl
01 Post treatment										
Cottraux 1990	16	8.50(7.30)	13	12.84(7.78)		_	-			-0.56 [-1.31, 0.19]
Subtotal (95% CI)	16		13							-0.56 [-1.31, 0.19]
Test for heterogeneity: not applica	able					_				
Test for overall effect: $Z = 1.47$ (F	P = 0.14)									
02.6 months follow-up										
Cottraux 1990	14	10.30(8.70)	11	13.50(3.11)		_	-			-0.45 [-1.25, 0.35]
Subtotal (95% CI)	14		11			-				-0.45 [-1.25, 0.35]
Test for heterogeneity: not applica	able									
Test for overall effect: $Z = 1.10$ (F	P = 0.27)									
03.1 year follow-up										
Cottraux 1990	12	9.70(9.90)	10	11.40(9.40)		_	_			-0.17 [-1.01, 0.67]
Subtotal (95% CI)	12		10				-			-0.17 [-1.01, 0.67]
Test for heterogeneity: not applica	able						1			
Test for overall effect: $Z = 0.39$ (F	P = 0.69)									
					-4	-2	ò	2	4	
					Favou	ırs ERP+FLV	/ Favo	ours Anti-E	RP+FLV	

Review: OCD: combination therapy

Comparison: 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine Outcome: 06 Target rituals (assessor): discomfort

Study or sub-category	N E	RP+Fluvoxamine Mean (SD)	Anti N	-ERP+Fluvoxamine Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl	
01 Post treatment							
Cottraux 1990	16	10.25(8.04)	13	11.30(10.27)	_ _	-0.11 [-0.84, 0.62]	
Subtotal (95% CI)	16		13		•	-0.11 [-0.84, 0.62]	
Fest for heterogeneity: not a	pplicable				ī	·	
est for overall effect: Z = 0	.30 (P = 0.76)						
02 6 months follow-up							
Cottraux 1990	14	12.21(9.25)	11	13.18(8.50)	_ _	-0.11 [-0.90, 0.69]	
Subtotal (95% CI)	14		11		•	-0.11 [-0.90, 0.69]	
est for heterogeneity: not a	applicable				ī		
est for overall effect: Z = 0	.26 (P = 0.79)						
03.1 year follow-up							
Cottraux 1990	12	11.50(10.90)	10	9.60(8.60)	 _	0.18 [-0.66, 1.03]	
Subtotal (95% CI)	12		10		-	0.18 [-0.66, 1.03]	
est for heterogeneity; not a	pplicable				T-		
est for overall effect: Z = 0							

Favours ERP+FLV Favours Anti-ERP+FLV

Favours ERP+FLV Favours Anti-ERP+FLV

Favours ERP+FLV Favours Anti-ERP+FLV

Review

OCD: combination therapy 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine Comparison: Outcome: 07 Target rituals (assessor): duration per day

ERP+Fluvoxamine SMD (fixed) Anti-ERP+Fluvoxamine SMD (fixed) Study 95% CI 95% CI N Mean (SD) or sub-category Mean (SD) 01 Post treatment -0.06 [-0.79, 0.68] -0.06 [-0.79, 0.68] Cottraux 1990 16 3.93(2.26) 13 4.07(2.56) Subtotal (95% CI) 16 13 Test for heterogeneity: not applicable Test for overall effect: Z = 0.15 (P = 0.88) 02.6 months follow-up Cottraux 1990 14 4.00(2.80) 11 4.09(2.59) -0.03 [-0.82, 0.76] Subtotal (95% CI) -0.03 [-0.82, 0.76] Test for heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94) 03.1 year follow-up -0.17 [-1.01, 0.67] -0.17 [-1.01, 0.67] Cottraux 1990 2.70(2.70) 10 3.20(3.10) Subtotal (95% CI) 10 12 Test for heterogeneity: not applicable Test for overall effect: Z = 0.39 (P = 0.70)

OCD: combination therapy

03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine 08 Behavioural avoidance test: discomfort

Comparison: Outcome:

Study	El	RP+Fluvoxamine	Anti-ERP+Fluvoxamine		SMD (fixed)		SMD (fixed)	
or sub-category N	N	Mean (SD)	N	Mean (SD)	95% CI		95% CI	
01 Post treatment								
Cottraux 1990	16	9.12(6.55)	13	11.46(6.75)	_		-0.34 [-1.08,	0.40]
Subtotal (95% CI)	16		13		•		-0.34 [-1.08,	0.40]
Test for heterogeneity: not a	pplicable				-			
Test for overall effect: $Z = 0$.91 (P = 0.36)							
02.1 year follow-up								
Cottraux 1990	12	10.20(9.20)	10	10.30(9.40)	_		-0.01 [-0.85,	0.83]
Subtotal (95% CI)	12		10		•		-0.01 [-0.85,	0.83]
Test for heterogeneity: not a	pplicable				T			
Test for overall effect: Z = 0	.02 (P = 0.98)							

Total (95% CI)

Test for heterogeneity: not applicable Test for overall effect: Z = 0.36 (P = 0.72)

Review: OCD: combination therapy Comparison: 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine Outcome 09 Compulsive activity checklist SMD (fixed) SMD (fixed) Study ERP+Fluvoxamine Anti-ERP+Fluvoxamine or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Post treatment Cottraux 1990 14.56(17.38) 13 21.53(12.56) -0.44 [-1.18, 0.30] 16 Subtotal (95% CI) 16 13 -0.44 [-1.18, 0.30] Test for heterogeneity: not applicable Test for overall effect: Z = 1.16 (P = 0.25) Cottraux 1990 Subtotal (95% CI) 12 15.50(17.60) 10 20.70(14.30) -0.31 [-1.15, 0.54] 12 10 -0.31 [-1.15, 0.54] Test for heterogeneity; not applicable Test for overall effect: Z = 0.72 (P = 0.47) 0 Favours ERP+FLV Favours Anti-ERP+FLV OCD: combination therapy Review: 04 CT + Fluvoxamine v CT Comparison: 01 Leaving the study early Outcome: Study CT + Fluvoxamine CT RR (fixed) RR (fixed) n/N 95% CI 95% CI or sub-category van Balkom 1998 10/24 1.74 [0.75, 4.03] 6/25 Total (95% CI) 10/24 6/25 1.74 [0.75, 4.03] Test for heterogeneity: not applicable Test for overall effect: Z = 1.28 (P = 0.20) 0.2 0.5 5 10 Favours CT+FLV Favours CT OCD: combination therapy Review: 04 CT + Fluvoxamine v CT Comparison: Outcome 02 Y-BOCS SMD (fixed) SMD (fixed) Study CT CT + Fluvoxamine or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI van Balkom 1998 14 15.60(5.40) 19 13.50(9.70) 0.25 [-0.44, 0.94] Total (95% CI) 19 0.25 [-0.44, 0.94] Test for heterogeneity: not applicable Test for overall effect: Z = 0.71 (P = 0.48) -0.5 0.5 Ò Favours CT+FLV Favours CT Review: OCD: combination therapy Comparison: 04 CT + Fluvoxamine v CT 03 Padua Inventory Outcome: Study CT + Fluvoxamine CT SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) N Mean (SD) 95% CI 95% CI van Balkom 1998 14 43.50(18.40) 19 49.10(23.60) -0.25 [-0.95, 0.44] Total (95% CI) 19 -0.25 [-0.95, 0.44] Test for heterogeneity; not applicable Test for overall effect: Z = 0.72 (P = 0.47) -0.5 Ó 0.5 Favours CT+FLV Favours CT OCD: combination therapy Review: 04 CT + Fluvoxamine v C1 Comparison: Outcome: 04 Beck Depression Inventory CT SMD (fixed) SMD (fixed) Study CT + Fluvoxamine or sub-category N Mean (SD) N Mean (SD) 95% CI 95% CI van Balkom 1998 14 10.80(6.60) 19 9.90(7.00) 0.13 [-0.56, 0.82]

-0.5

Ó Favours CT+FLV Favours CT 0.13 [-0.56, 0.82]

19

Review: OCD: combination therapy Comparison: 04 CT + Fluvoxamine v C Outcome 05 Symptom Checklist-90 CT + Fluvoxamine SMD (fixed) Study CT SMD (fixed) or sub-category N Mean (SD) N Mean (SD) 95% CI 95% CI van Balkom 1998 162.00(42.70) 19 163.40(44.40) -0.03 [-0.72, 0.66] 14 Total (95% CI) -0.03 [-0.72, 0.66] Test for heterogeneity: not applicable Test for overall effect: Z = 0.09 (P = 0.93) -0.5 ò 0.5 Favours CT+FLV Favours CT OCD: combination therapy Review: 04 CT + Fluvoxamine v CT Comparison 06 Anxiety Discomfort Scale: patient's ratings Outcome SMD (fixed) SMD (fixed) Study CT + Fluvoxamine CT Mean (SD) or sub-category Ν Mean (SD) Ν 95% CI 95% CI van Balkom 1998 13.00(4.90) 19 12.50(9.30) 0.06 [-0.63, 0.75] Total (95% CI) 19 0.06 [-0.63] 0.751 Test for heterogeneity: not applicable Test for overall effect: Z = 0.18 (P = 0.86) -0.5 0.5 Ó Favours CT+FLV Favours CT Review: OCD: combination therapy Comparison: 04 CT + Fluvoxamine v CT Outcome 07 Anxiety Discomfort Scale: therapist's ratings Study CT + Fluvoxamine CT SMD (fixed) SMD (fixed) Ν or sub-category Mean (SD) Ν Mean (SD) 95% CI 95% CI van Balkom 1998 14 13.60(7.50) 19 13.10(10.20) 0.05 [-0.64, 0.74] Total (95% CI) 19 0.05 [-0.64, 0.74] Test for heterogeneity; not applicable Test for overall effect: Z = 0.15 (P = 0.88) -0.5 Ó 0.5 Favours CT+FLV Favours CT OCD: combination therapy Review: 04 CT + Fluvoxamine v C1 Comparison: Outcome 08 Anxiety Discomfort Scale: assessor's ratings СТ SMD (fixed) SMD (fixed) Study + Fluvoxamine or sub-category N Mean (SD) N Mean (SD) 95% CI 95% CI van Balkom 1998 14 13.80(4.70) 19 12.50(9.50) 0.16 [-0.53, 0.85] Total (95% CI) 19 0.16 [-0.53, 0.85] Test for heterogeneity: not applicable Test for overall effect: Z = 0.46 (P = 0.65) -0.5 0.5 Favours CT+FLV Favours CT Review: OCD: combination therapy Comparison: 05 ERP + Fluvoxamine v CT + Fluvoxamine Outcome: 01 Leaving the study early RR (fixed) RR (fixed) Study ERP + Fluvoxamine CT + Fluvoxamine 95% CI or sub-category n/N n/N 95% CI van Balkom 1998 10/28 10/24 0.86 [0.43, 1.70] Total (95% CI) 10/24 10/28 0.86 [0.43, 1.70] Test for heterogeneity: not applicable Test for overall effect: Z = 0.44 (P = 0.66) 0.1 0.2 0.5 5 10 Favours ERP+FLV Favours CT+FLV OCD: combination therapy Comparison: 05 ERP + Fluvoxamine v CT + Fluvoxamine 02 Y-BOCS Outcome Study ERP + Fluvoxamine CT + Fluvoxamine SMD (fixed) SMD (fixed) or sub-category N Mean (SD) M Mean (SD) 95% CI 95% CI van Balkom 1998 12.60(6.60) 15.60(5.40) -0.48 [-1.19, 0.23] 18 14 Total (95% CI) 14 -0.48 [-1.19, 0.23] Test for heterogeneity: not applicable Test for overall effect: Z = 1.32 (P = 0.19)

-2

Ó Favours ERP+FLV Favours CT+FLV

Review: OCD: combination therapy Comparison: 05 ERP + Fluvoxamine v CT + Fluvoxamine Outcome 03 Padua Inventory SMD (fixed) Study ERP + Fluvoxamine CT + Fluvoxamine SMD (fixed) or sub-category N Mean (SD) N Mean (SD) 95% CI 95% CI van Balkom 1998 18 43.20(23.50) 43.50(18.40) -0.01 [-0.71. 0.68] 14 Total (95% CI) -0.01 [-0.71, 0.68] Test for heterogeneity: not applicable Test for overall effect: Z = 0.04 (P = 0.97) -0.5 ò 0.5 Favours ERP+FLV Favours CT+FLV OCD: combination therapy Review: 05 ERP + Fluvoxamine v CT + Fluvoxamine Comparison 04 Beck Depression Inventory Outcome SMD (fixed) SMD (fixed) Study ERP + Fluvoxamine CT + Fluvoxamine Ν or sub-category Ν Mean (SD) Mean (SD) 95% CI 95% CI van Balkom 1998 18 10.10(7.20) 14 10.80(6.60) -0.10 [-0.80, 0.60] Total (95% CI) -0.10 [-0.80, 0.60] 18 14 Test for heterogeneity: not applicable Test for overall effect: Z = 0.28 (P = 0.78) -0.5 0.5 0 Favours ERP+FLV Favours CT+FLV Review: OCD: combination therapy 05 FRP + Fluvoxamine v CT + Fluvoxamine Comparison: 05 Symptom Checklist-90 Outcome Study ERP + Fluvoxamine CT + Fluvoxamine SMD (fixed) SMD (fixed) Ν or sub-category Mean (SD) Ν Mean (SD) 95% CI 95% CI van Balkom 1998 18 154.50(51.40) 14 162.00(42.70) -0.15 [-0.85, 0.55] Total (95% CI) 18 14 -0.15 [-0.85, 0.55] Test for heterogeneity; not applicable Test for overall effect: Z = 0.43 (P = 0.67) -0.5 Ó 0.5 Favours ERP+FLV Favours CT+FLV OCD: combination therapy Review: Comparison: 05 ERP + Fluvoxamine v CT + Fluvoxamine Outcome 06 Anxiety Discomfort Scale: patient's ratings CT + Fluvoxamine SMD (fixed) SMD (fixed) Study + Fluvoxamine or sub-category N Mean (SD) N Mean (SD) 95% CI 95% CI 0.00 [-0.70, 0.70] van Balkom 1998 18 13.00(4.90) 14 13.00(4.90) Total (95% CI) 14 0.00 [-0.70, 0.70] 18 Test for heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.00)-0.5 0.5 Favours ERP+FLV Favours CT+FLV OCD: combination therapy Review: 05 ERP + Fluvoxamine v CT + Fluvoxamine Comparison: 07 Anxiety Discomfort Scale: therapist's ratings Outcome SMD (fixed) SMD (fixed) Study + Fluvoxamine CT + Fluvoxamine Ν Ν 95% CI or sub-category Mean (SD) 95% CI Mean (SD) van Balkom 1998 18 14.20(10.30) 14 13.60(7.50) 0.06 [-0.64, 0.76] Total (95% CI) 14 0.06 [-0.64] 0.761 18 Test for heterogeneity: not applicable Test for overall effect: Z = 0.18 (P = 0.86) -0.5 0.5 Ó Favours ERP+FLV Favours CT+FLV Review: OCD: combination therapy 05 ERP + Fluvoxamine v CT + Fluvoxamine Comparison: 08 Anxiety Discomfort Scale: assessor's ratings Outcome ERP + Fluvoxamine CT + Fluvoxamine SMD (fixed) SMD (fixed) Study or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI van Balkom 1998 14.20(8.70) 13.80(4.70) 0.05 [-0.64, 0.75] 18 14 Total (95% CI) 18 14 0.05 [-0.64, 0.75] Test for heterogeneity: not applicable Test for overall effect: Z = 0.15 (P = 0.88)

-0.5

Ó

Favours ERP+FLV Favours CT+FLV

0.5

OCD: combination therapy Review:

06 Children: ERP + Fluvoxamine v Fluvoxamine alone Comparison: Outcome: 01 Non-responder (Y-BOCS reliable change)

Study or sub-category	ERP + Fluvoxamine n/N	Fluvoxamine n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 At 43 weeks				
Neziroglu 2000	0/5	3/5		0.14 [0.01, 2.21]
Subtotal (95% CI)	0/5	3/5		0.14 [0.01, 2.21]
Test for heterogeneity: not ap	pplicable		-	•
Test for overall effect: $Z = 1.3$	39 (P = 0.16)			
02 At 52 weeks				
Neziroglu 2000	0/5	2/5		0.20 [0.01, 3.35]
Subtotal (95% CI)	0/5	2/5		0.20 [0.01, 3.35]
Test for heterogeneity: not ap	pplicable			
Test for overall effect: $Z = 1.1$	12 (P = 0.26)			
03 At 2 years				
Neziroglu 2000	0/5	2/5		0.20 [0.01, 3.35]
Subtotal (95% CI)	0/5	2/5		0.20 [0.01, 3.35]
Test for heterogeneity: not ap	pplicable			•
Test for overall effect: Z = 1.1	•			
	· · ·	0.0	01 0.01 0.1 1 10 100	1000

Favours ERP+FLV Favours FLV

Favours ERP+FLV Favours FLV

OCD: combination therapy Review:

Comparison: 06 Children: ERP + Fluvoxamine v Fluvoxamine alone

Outcome: 02 CY-BOCS

SMD (fixed) 95% CI		SMD (fixed) 95% Cl	Fluvoxamine Mean (SD)	N	RP + Fluvoxamine Mean (SD)	N E	Study or sub-category
							01 At 43 weeks
1 [-2.93, 0.04]	-1.44 [-2.93		-3.60(4.28)	5	-11.60(5.64)	5	Neziroglu 2000
4 [-2.93, 0.04]	-1.44 [-2.93			5		5	Subtotal (95% CI)
						pplicable	est for heterogeneity: not ap
						.91 (P = 0.06)	est for overall effect: $Z = 1.9$
							2 At 52 weeks
[-3.00, 0.00]	-1.50 [-3.00		-3.40(6.69)	5	-14.00(6.08)	5	Neziroglu 2000
[-3.00, 0.00]	-1.50 [-3.00			5		5	ubtotal (95% CI)
						pplicable	est for heterogeneity: not ap
						.96 (P = 0.05)	est for overall effect: $Z = 1.9$
							3 At 2 years
3 [-2.65, 0.19]	-1.23 [-2.65		-9.00(11.42)	5	-20.20(2.17)	5	Neziroglu 2000
3 [-2.65, 0.19]	-1.23 [-2.65			5		5	ubtotal (95% CI)
		-				pplicable	est for heterogeneity: not ap
						.70 (P = 0.09)	est for overall effect: Z = 1.3
-	4	-4 -2 0 2					Test for heterogeneity: not ap Test for overall effect: Z = 1.7

Review: OCD: combination therapy

06 Children: ERP + Fluvoxamine v Fluvoxamine alone 03 NIMH-GOCS Comparison:

Outcome:

Study or sub-category	N E	RP + Fluvoxamine Mean (SD)	N	Fluvoxamine Mean (SD)		S	SMD (fixed) 95% CI			SMD (fixed) 95% Cl
Neziroglu 2000	5	-4.00(1.58)	5	-2.80(2.39)			-			-0.54 [-1.81, 0.74]
Subtotal (95% CI)	5		5				•			-0.54 [-1.81, 0.74]
est for heterogeneity: not applicab	le						٦			•
Test for overall effect: Z = 0.82 (P =										
02 At 52 weeks										
Neziroglu 2000	5	-3.80(2.17)	5	-2.20(2.39)			-			-0.63 [-1.92, 0.66]
Subtotal (95% CI)	5		5				-			-0.63 [-1.92, 0.66]
Fest for heterogeneity: not applicab	le						_			
est for overall effect: Z = 0.96 (P =										
03 At 2 years										
Neziroglu 2000	5	-7.40(2.88)	5	-4.00(4.53)			-			-0.81 [-2.13, 0.51]
ubtotal (95% CI)	5		5				-			-0.81 [-2.13, 0.51]
est for heterogeneity: not applicab	le						_			
est for overall effect: Z = 1.20 (P =										
					-10	-5	ó	5	10	
					Favour	s ERP+F	LV Favo	ours FLV		

Test for heterogeneity: not applicable Test for overall effect: Z = 1.13 (P = 0.26)

OCD: combination therapy Review: 07 Children: CBT + Sertraline v Sertraline Comparison: Outcome: 01 Leaving the study early CBT + Sertraline Sertraline RR (fixed) RR (fixed) Study 95% CI or sub-category n/Ν n/Ν 95% CI POTS 2004 1.00 [0.22, 4.54] 3/28 3/28 Total (95% CI) 3/28 3/28 1.00 [0.22, 4.54] Test for heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.00)0.1 0.2 0.5 5 10 Favours CBT+Sertrali Favours Sertraline Review: OCD: combination therapy 07 Children: CBT + Sertraline v Sertraline Comparison: Outcome: 02 Leaving the study early due to adverse events RR (fixed) RR (fixed) Study CBT + Sertraline Sertraline or sub-category n/Ν n/N 95% CI 95% CI POTS 2004 1/28 1/28 1.00 [0.07, 15.21] Total (95% CI) 1/28 1.00 [0.07, 15.21] 1/28 Test for heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.00)0.1 0.2 0.5 ż 5 10 Favours CBT+Sertrali Favours Sertraline Review: OCD: combination therapy Comparison: 07 Children: CBT + Sertraline v Sertraline Outcome 03 CY-BOCS CBT + Sertraline Sertraline SMD (fixed) SMD (fixed) or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CL POTS 2004 11.20(8.60) 28 16.50(9.10) -0.59 [-1.13, -0.05] 28 Total (95% CI) 28 -0.59 [-1.13, -0.05] Test for heterogeneity; not applicable Test for overall effect: Z = 2.16 (P = 0.03) -0.5 Ó 0.5 Favours CBT+Sertrali Favours Sertraline OCD: combination therapy Review: Comparison: 08 Children: CBT + Sertraline v CBT Outcome: 01 Leaving the study early Study CBT + Sertraline Sertraline RR (fixed) RR (fixed) 95% CI 95% CI n/N n/N or sub-category POTS 2004 1.00 [0.22, 4.54] 3/28 3/28 Total (95% CI) 3/28 3/28 1.00 [0.22, 4.54] Test for heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.00) 0.1 0.2 0.5 2 5 10 Favours CBT+Sertrali Favours Sertraline Review: OCD: combination therapy 08 Children: CBT + Sertraline v CBT Comparison: Outcome 02 CY-BOCS Study CBT + Sertraline Sertraline SMD (fixed) SMD (fixed) Ν Ν Mean (SD) or sub-category Mean (SD) 95% CI 95% CI POTS 2004 11.20(8.60) 28 14.00(9.50) -0.30 [-0.83, 0.22] Total (95% CI) 28 28 -0.30 [-0.83, 0.22]

-0.5

Favours CBT+Sertrali

Ó

0.5

Favours Sertraline

Total (95% CI)

Test for heterogeneity: not applicable Test for overall effect: Z = 0.28 (P = 0.78)

Other medical interventions OCD: other medical Review: Comparison: 01 Stereotactic anterior capsulotomy vs cinquiotomy 01 CPRS @ 3 months; change score Outcome Cingulotomy SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 2 Fodstad 1982 -5.75(1.06) 2 -13.75(0.35) -5.79 [-38.62, 27.03] Total (95% CI) 2 -5.79 [-38.62, 27.03] Test for heterogeneity; not applicable Test for overall effect: Z = 0.35 (P = 0.73) -100 -50 Ó 50 100 Favours capsulotomy Favours cingulotomy Review: OCD: other medical Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy 02 CPRS @ 6 months: change score Outcome SMD (fixed) SMD (fixed) Study Capsulotomy Cinquiotomy Mean (SD) Mean (SD) 95% CI 95% CI or sub-category Fodstad 1982 -13.25(5.30) 2 -11.25(1.06) -0.30 [-2.89, 2.29] Total (95% CI) -0.30 [-2.89, 2.29] Test for heterogeneity: not applicable Test for overall effect: Z = 0.23 (P = 0.82) Ó Favours cingulatomy Favours capsulotomy Review: OCD: other medical Comparison: 01 Stereotactic anterior capsulotomy vs cinquiotomy 03 CPRS @ 12 months: change score Outcome Study Capsulotomy Cingulotomy SMD (fixed) SMD (fixed) Ν or sub-category Ν Mean (SD) Mean (SD) 95% CI 95% CL Fodstad 1982 2 -13.50(2.83) -17.25(6.01) 0.46 [-2.78, 3.70] 2 Total (95% CI) 2 0.46 [-2.78, 3.70] Test for heterogeneity; not applicable Test for overall effect: Z = 0.28 (P = 0.78) -2 Ò Favours cinquiotomy Favours capsulotomy OCD: other medical Review: Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy Outcome 04 HAM-D @ 3 months: change score Study Cingulotomy SMD (fixed) SMD (fixed) Capsulotomy or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI 0.19 [-2.05, 2.43] Fodstad 1982 -3.00(4.24) -4.00(0.01) 2 2 Total (95% CI) 2 0.19 [-2.05, 2.43] Test for heterogeneity: not applicable Test for overall effect: Z = 0.17 (P = 0.87) ò -2 Favours capsulotomy Favours cingulatomy Review: OCD: other medical Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy Outcome 05 HAM-D @ 6 months: change score SMD (fixed) SMD (fixed) Study Capsulotomy Cinquiotomy Mean (SD) N Mean (SD) 95% CI 95% CI or sub-category Fodstad 1982 2 -2.00(5.66) 2 -2.00(2.83) 0.00 [-1.96, 1.96] Total (95% CI) 0.00 [-1.96, 1.96] Test for heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.00) Ó Favours capsulotomy Favours cingulatomy Review: OCD: other medical Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy 06 HAM-D @ 12 months: change score Outcome SMD (fixed) Capsulotomy Cingulotomy SMD (fixed) or sub-category M Mean (SD) M Mean (SD) 95% CI 95% CL Fodstad 1982 2 -1.50(4.95) -4.50(0.71) 0.48 [-2.89, 3.86]

-2

Favours capsulotomy

ń

Favours cingulatomy

0.48 [-2.89, 3.86]

2

Review: OCD: other medical Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy Outcome 07 HAM-A @ 3 months; change score SMD (fixed) SMD (fixed) Study Capsulotomy Cingulotomy or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI Fodstad 1982 2 -4.00(1.41) 2 -11.50(12.02) 0.50 [-2.94, 3.95] Total (95% CI) 0.50 [-2.94, 3.95] Test for heterogeneity: not applicable Test for overall effect: Z = 0.28 (P = 0.78) ò Favours capsulotomy Favours cingulatomy OCD: other medical Review: Comparison 01 Stereotactic anterior capsulotomy vs cinquiotomy 08 HAM-A @ 6 months: change score Outcome SMD (fixed) SMD (fixed) Study Capsulotomy Cinquiotomy Ν or sub-category Ν Mean (SD) Mean (SD) 95% CI 95% CI Fodstad 1982 2 -3.00(2.83) 2 -6.00(5.66) 0.38 [-2.54, 3.31] Total (95% CI) 2 0.38 [-2.54] 3.311 Test for heterogeneity: not applicable Test for overall effect: Z = 0.26 (P = 0.80) -2 Ó Favours cingulatomy Favours capsulotomy Review: OCD: other medical Comparison: 01 Stereotactic anterior capsulotomy vs cinquiotomy 09 HAM-A @ 12 months: change score Outcome Capsulotomy Study Cingulotomy SMD (fixed) SMD (fixed) Ν Ν or sub-category Mean (SD) Mean (SD) 95% CI 95% CI Fodstad 1982 2 -2.50(3.54) -7.50(7.78) 0.47 [-2.84, 3.79] Total (95% CI) 2 0.47 [-2.84, 3.79] Test for heterogeneity; not applicable Test for overall effect: Z = 0.28 (P = 0.78) -2 ń Favours capsulotomy Favours cingulatomy OCD: other medical Review: 02 Repetitive transcranial magnetic stimulation; active vs placebo Comparison: Outcome: 01 Adverse effects Study Active RTMS Placebo RTMS RR (fixed) RR (fixed) 95% CI 95% CI or sub-category n/N n/Ν Alonso 2001 1/10 0/8 2.45 [0.11, 53.25] Total (95% CI) 10 8 2.45 [0.11, 53.25] Total events: 1 (Active RTMS), 0 (Placebo RTMS) Test for heterogeneity: not applicable Test for overall effect: Z = 0.57 (P = 0.57) 0.01 0.1 100 10 Favours active RTMS Favours placebo RTMS OCD: other medical Review: Comparison: 02 Repetitive transcranial magnetic stimulation; active vs placebo Outcome: 02 Non-responders (Y-BOCS 40%) Study Active RTMS Placebo RTMS RR (fixed) RR (fixed) or sub-category n/Ν n/Ν 95% CI 95% CI Alonso 2001 8/10 7/8 0.91 [0.61, 1.37] Total (95% CI) 10 8 0.91 [0.61, 1.37] Total events: 8 (Active RTMS), 7 (Placebo RTMS) Test for heterogeneity: not applicable Test for overall effect: Z = 0.43 (P = 0.67)


0.7

Favours active RTMS

1.5

Favours placebo RTMS


Review: OCD: other medical Comparison: 02 Repetitive transcranial magnetic stimulation; active vs placebo Outcome 03 Y-BOCS: change score SMD (fixed) SMD (fixed) Study Active RTMS Placebo RTMS or sub-category N Mean (SD) N Mean (SD) 95% CI 95% CI Alonso 2001 10 -3.40(8.24) 8 -0.25(3.92)-0.45 [-1.39. 0.50] Total (95% CI) -0.45 [-1.39, 0.50] Test for heterogeneity: not applicable Test for overall effect; Z = 0.93 (P = 0.35) ò Favours active RTMS Favours placebo RTMS OCD: other medical Review: Comparison 02 Repetitive transcranial magnetic stimulation; active vs placebo 04 HAM-D: change score Active RTMS Placebo RTMS SMD (fixed) SMD (fixed) Study or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI Alonso 2001 10 -0.30(3.95) 0.25(1.16) -0.17 [-1.10, 0.76] Total (95% CI) 8 -0.17 [-1.10. 0.76] 10 Test for heterogeneity: not applicable Test for overall effect: Z = 0.36 (P = 0.72) -2 0 Favours active RTMS Favours placebo RTMS Review: OCD: other medical 03 Repetitive transcranial magnetic stimulation; right vs left Comparison: 01 Y-BOCS @ post-treatment Outcome Study Right Left SMD (fixed) SMD (fixed) Ν Mean (SD) Ν or sub-category Mean (SD) 95% CI 95% CI 01 Right prefrontal v Left prefrontal Sachdev 2001 17.00(4.86) 16.67(12.31) 0.03 [-1.10, 1.16] Subtotal (95% CI) 0.03 [-1.10, 1.16] Test for heterogeneity; not applicable Test for overall effect: Z = 0.06 (P = 0.96) -4 -2 ń Favours right Favours left OCD: other medical Review: 03 Repetitive transcranial magnetic stimulation; right vs left Comparison: Outcome 02 BDI @ post-treatment Left SMD (fixed) SMD (fixed) Study Right or sub-category Ν Mean (SD) N Mean (SD) 95% CI 95% CI 01 Right prefrontal v Left prefrontal Sachdev 2001 14.17(8.91) 9.67(8.26) 0.48 [-0.67, 1.64] Subtotal (95% CI) 0.48 [-0.67, 1.64] Test for heterogeneity: not applicable Test for overall effect: Z = 0.82 (P = 0.41) Favours right Favours left OCD: other medical Review: Comparison: 03 Repetitive transcranial magnetic stimulation; right vs left Outcome 03 MADRS @ post-treatment SMD (fixed) SMD (fixed) Study Right Left Mean (SD) N Mean (SD) 95% CI or sub-category Ν 95% CI 01 Right prefrontal v Left prefrontal Sachdey 2001 15.33(10.35) 6 6.00(7.51) 0.95 [-0.27, 2.18] Subtotal (95% CI) 0.95 [-0.27, 2.18] Test for heterogeneity: not applicable Test for overall effect: Z = 1.53 (P = 0.13) 0 Favours right Favours left Review: OCD: other medical Comparison: 03 Repetitive transcranial magnetic stimulation; right vs left Outcome 04 STAI-S @ post-treatment SMD (fixed) SMD (fixed) Left or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Right prefrontal v Left prefrontal Sachdev 2001 45.50(9.67) 45.00(15.02) 0.04 [-1.10, 1.17] Subtotal (95% CI) 0.04 [-1.10, 1.17] Test for heterogeneity: not applicable Test for overall effect: Z = 0.06 (P = 0.95) -4 -2 Ò ż 4 Favours right Favours left



Review: OCD: other medical

Comparison: 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment)

Outcome: 01 Adverse effects



Review: OCD: other medical

Comparison: 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment)

Outcome: 02 Leaving study early

Study or sub-category	Treatment 1 n/N	Treatment 2 n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
	bo			
Perlmutter 1999	0/10	0/10		Not estimable
Subtotal (95% CI)	o	0		Not estimable
otal events: 0 (Treatment 1),	0 (Treatment 2)			
est for heterogeneity: not app	•			
Test for overall effect: not app	plicable			
02 IV immunoglobulin vs place	bo			
Perlmutter 1999	1/10	0/10		— 3.00 [0.14 , 65.90]
Subtotal (95% CI)	10	10		3.00 [0.14, 65.90]
Fotal events: 1 (Treatment 1),	0 (Treatment 2)		- -	
Fest for heterogeneity: not app	plicable			
Test for overall effect: $Z = 0.7$	0 (P = 0.49)			
03 Plasma exchange vs IV imr	nunoglobulin			
Perlmutter 1999	0/10	1/10		0.33 [0.02, 7.32]
Subtotal (95% CI)	10	10		0.33 [0.02, 7.32]
otal events: 0 (Treatment 1),	1 (Treatment 2)		_	
est for heterogeneity: not app	plicable			
Test for overall effect: $Z = 0.7$	0 (P = 0.49)			
		0.0	1 0.1 1 10	100
		Fa	vours Treatment 1 Favours Treat	tment 2

Review: OCD: other medical

Comparison: 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment)

Outcome: 03 Y-BOCS*

Study or sub-category	N	Treatment 1 Mean (SD)	N	Treatment 2 Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% Cl	
	0						
Perlmutter 1999	5	18.20(6.10)	7	29.71(3.55)		-2.24 [-3.83, -0.66]	
Subtotal (95% CI)	5		7			-2.24 [-3.83, -0.66]	
Test for heterogeneity: not appl	icable					·	
Test for overall effect: $Z = 2.77$	(P = 0.006)						
02 IV immunoglobulin vs placeb	0						
Perlmutter 1999	6	17.83(9.68)	7	29.71(3.55)		-1.57 [-2.88, -0.26]	
Subtotal (95% CI)	6		7		-	-1.57 [-2.88, -0.26]	
Test for heterogeneity: not appl	icable				_		
Fest for overall effect: $Z = 2.35$	(P = 0.02)						
03 Plasma exchange vs IV immu	unoglobulin						
Perlmutter 1999	5	18.20(6.10)	6	17.83(9.68)		0.04 [-1.15, 1.23]	
Subtotal (95% CI)	5		6		-	0.04 [-1.15, 1.23]	
Test for heterogeneity: not appl	icable				T		
Test for overall effect: $Z = 0.07$	(P = 0.95)						

Favours Treatment 1 Favours Treatment 2

Favours Treatment 1 Favours Treatment 2

Favours Treatment 1 Favours Treatment 2

Review:

OCD: other medical 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment) Comparison:

Outcome: 04 NIMH-Global Severity*

Study or sub-category	N	Treatment 1 Mean (SD)	N	Treatment 2 Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl	
	ebo						
Perlmutter 1999	5	6.33(2.30)	7	8.29(0.76)		-1.15 [-2.43, 0.13]	
Subtotal (95% CI)	5		7			-1.15 [-2.43, 0.13]	
est for heterogeneity; not ap	pplicable				_		
Test for overall effect: $Z = 1$.	77 (P = 0.08)						
02 IV immunoglobulin vs plac	ebo						
Perlmutter 1999	6	6.33(1.97)	7	8.29(0.76)		-1.26 [-2.50, -0.03]	
Subtotal (95% CI)	6		7		-	-1.26 [-2.50, -0.03]	
est for heterogeneity: not ap	pplicable						
est for overall effect: $Z = 2$.	00 (P = 0.04)						
3 Plasma exchange vs IV im	munoglobulin						
Perlmutter 1999	5	6.33(2.30)	6	6.33(1.97)		0.00 [-1.19, 1.19]	
Subtotal (95% CI)	5		6			0.00 [-1.19, 1.19]	
est for heterogeneity: not ap	pplicable				T		
est for overall effect: Z = 0.							

Comparison: Outcome: 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment) 05 CGI-Symptom Severity*

tudy r sub-category	Treatment 1 Treatment 2 SMD (fixed) ory N Mean (SD) N Mean (SD) 95% CI			SMD (fixed) 95% Cl		
l Plasma exchange vs place	bo					
Perlmutter 1999	5	3.60(1.14)	7	4.86(0.48)		-1.43 [-2.78, -0.09]
ubtotal (95% CI)	5		7			-1.43 [-2.78, -0.09]
est for heterogeneity: not ap	plicable					
est for overall effect: $Z = 2.0$	9 (P = 0.04)					
2 IV immunoglobulin vs place	bo					
Perlmutter 1999	6	3.92(1.11)	7	4.86(0.48)		-1.06 [-2.25, 0.14]
ubtotal (95% CI)	6		7			-1.06 [-2.25, 0.14]
est for heterogeneity: not ap	plicable				 -	
est for overall effect: $Z = 1.7$	3 (P = 0.08)					
3 Plasma exchange vs IV imi	munoglobulin					
Perlmutter 1999	5	3.60(1.14)	6	3.92(1.11)		-0.26 [-1.45, 0.93]
ubtotal (95% CI)	5		6			-0.26 [-1.45, 0.93]
est for heterogeneity: not ap	plicable				7	•
est for overall effect: Z = 0.4	3 (P = 0.67)					

Review: OCD: other medical

Comparison: 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment)

Outcome: 06 Global Assessment Scale*

Study or sub-category	N	Treatment 1 Mean (SD)	N	Treatment 2 Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% CI	
01 Plasma exchange vs placeb	10						
Perlmutter 1999	5	-63.40(12.36)	7	-54.86(4.30)		-0.93 [-2.16, 0.31]	
Subtotal (95% CI)	5		7			-0.93 [-2.16, 0.31]	
Test for heterogeneity: not app	licable						
Test for overall effect: $Z = 1.47$	(P = 0.14)						
02 IV immunoglobulin vs placeb	10						
Perlmutter 1999	6	-62.83(10.69)	7	-54.86(4.30)		-0.94 [-2.11, 0.23]	
Subtotal (95% CI)	6		7			-0.94 [-2.11, 0.23]	
Test for heterogeneity: not app	licable				-		
Test for overall effect: $Z = 1.57$	(P = 0.12)						
03 Plasma exchange vs IV imm	unoalobulin						
Perlmutter 1999	5	-63.40(12.36)	6	-62.83(10.69)	 _	-0.05 [-1.23, 1.14]	
Subtotal (95% CI)	5		6			-0.05 [-1.23, 1.14]	
Test for heterogeneity: not app	licable				-T		
Test for overall effect: Z = 0.08							

Favours Treatment 1 Favours Treatment 2

OCD: other medical Review:

Comparison: 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment)

Outcome:

Study or sub-category	N	Treatment 1 Mean (SD)	N	Treatment 2 Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl	
	00						
Perlmutter 1999	5	4.20(2.28)	7	7.00(1.41)		-1.43 [-2.77, -0.09]	
Subtotal (95% CI)	5		7			-1.43 [-2.77, -0.09]	
Test for heterogeneity: not app	licable						
Test for overall effect: Z = 2.09							
02 IV immunoglobulin vs placek	00						
Perlmutter 1999	6	5.33(1.37)	7	7.00(1.41)		-1.12 [-2.32, 0.09]	
Subtotal (95% CI)	6		7			-1.12 [-2.32, 0.09]	
Fest for heterogeneity: not app	licable				-		
Fest for overall effect: Z = 1.8	1 (P = 0.07)						
D3 Plasma exchange vs IV imm	unoglobulin						
Perlmutter 1999	5	4.20(2.28)	6	5.33(1.37)		-0.56 [-1.79, 0.66]	
Subtotal (95% CI)	5		6	•		-0.56 [-1.79, 0.66]	
Test for heterogeneity: not app	licable						
Test for overall effect: $Z = 0.90$							

Favours Treatment 1 Favours Treatment 2 OCD: other medical


04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment) 08 NIMH-Depression* Comparison: Outcome:

Study or sub-category N	1	Treatment 1 Mean (SD)	N	Treatment 2 Mean (SD)		S	MD (fixed) 95% Cl			SMD (fixed) 95% Cl
01 Plasma exchange vs placebo										
Perlmutter 1999	5	3.60(2.19)	7	7.57(2.30)	-		—			-1.62 [-3.02, -0.23]
Subtotal (95% CI)	5		7		-		⊨			-1.62 [-3.02, -0.23]
Test for heterogeneity: not applicable						_				
Test for overall effect: $Z = 2.28$ (P = 0	0.02)									
02 IV immunoglobulin vs placebo										
Perlmutter 1999	6	4.83(2.14)	7	7.57(2.30)			_			-1.14 [-2.35, 0.07]
Subtotal (95% CI)	6		7			-				-1.14 [-2.35, 0.07]
Test for heterogeneity: not applicable							_			
Test for overall effect: Z = 1.85 (P = 0										
03 Plasma exchange vs IV immunoglo	bulin									
Perlmutter 1999	5	3.62(0.19)	6	4.83(2.14)						-0.69 [-1.93, 0.55]
Subtotal (95% CI)	5		6			-				-0.69 [-1.93, 0.55]
Test for heterogeneity: not applicable						_	_			,
Test for overall effect: $Z = 1.09$ (P = 0	0.27)									
					-4	-2	ò	2	4	
					Favour	s Treatmer	t1 Fav	ours Treat	nent 2	

Review: OCD: other medical

Comparison: 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment)

Outcome: 09 NIMH-OC*



Favours Treatment 1 Favours Treatment 2

Review: OCD: other medical

Comparison: 05 Plasma exchange vs IV immunoglobulin (child/adolescent: at 1 year after start of treatment)

Outcome: 01 Leaving study early

Study or sub-category	Plasma exchange n/N	IV immunoglobulin n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Perimutter 1999	2/10	0/9		4.55 [0.25, 83.70]
Total (95% CI) Total events: 2 (Plasma exc Test for heterogeneity: not Test for overall effect: Z =	• •	9		4.55 [0.25, 83.70]
		0.01	0.1 1 10 10	00

Favours plasma exch. Favours IV immu.

Review: OCD: other medical

Comparison: 05 Plasma exchange vs IV immunoglobulin (child/adolescent: at 1 year after start of treatment)

Outcome: 02 Y-BOCS*

Study or sub-category	P N	lasma exchange Mean (SD)	N IV	' immunoglobulin Mean (SD)			MD (fixed) 95% Cl		SMD (fixed) 95% Cl
Perlmutter 1999	5	10.50(8.27)	6	12.00(2.45)			-		-0.24 [-1.43, 0.96]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0			6		,	-	•	,	-0.24 [-1.43, 0.96]
					-4	-2	ó	ż	4

Favours plasma exch. Favours IV immu.

Review: OCD: other medical

Comparison: 05 Plasma exchange vs IV immunoglobulin (child/adolescent: at 1 year after start of treatment)

Outcome: 03 Global Assessment Scale*

